Literature DB >> 24512943

Offenders with mental health problems and problematic substance use: affective psychopathic personality traits as potential barriers to participation in substance abuse interventions.

Natalie Durbeej1, Tom Palmstierna2, Anne H Berman3, Marianne Kristiansson3, Clara Hellner Gumpert3.   

Abstract

Substance abuse is related to re-offending, and treatment of substance abuse may reduce criminal recidivism. Offender characteristics including problem severity, violence risk and psychopathic personality traits may be positively or negatively associated with participation in substance abuse treatment. We explored the relationships between such characteristics and participation in substance abuse interventions among Swedish offenders with mental health problems and problematic substance use. Our analyses revealed that problem severity regarding drugs, employment, and family/social situations predicted intervention participation, and that affective psychopathic personality traits were negatively associated with such participation. Thus, affective psychopathic personality traits could be considered as potential barriers to participation in substance abuse interventions. Among offenders with mental health problems and problematic substance use, such personality traits should be taken into account in order to optimize treatment participation and treatment outcome. Approaches used in cognitive-behavioral therapy (CBT) and dialectical behavioral therapy (DBT) could be applicable for these patients.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Problem severity; Psychopathic personality traits; Recidivism; Substance abuse treatment; Violence risk

Mesh:

Year:  2014        PMID: 24512943     DOI: 10.1016/j.jsat.2014.01.002

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  7 in total

Review 1.  [Standards for treatment in forensic committment according to § 63 and § 64 of the German criminal code : Interdisciplinary task force of the DGPPN].

Authors:  J L Müller; N Saimeh; P Briken; S Eucker; K Hoffmann; M Koller; T Wolf; M Dudeck; C Hartl; A-K Jakovljevic; V Klein; G Knecht; R Müller-Isberner; J Muysers; K Schiltz; D Seifert; A Simon; H Steinböck; W Stuckmann; W Weissbeck; C Wiesemann; R Zeidler
Journal:  Nervenarzt       Date:  2017-08       Impact factor: 1.214

2.  A test of core psychopathic traits as a moderator of the efficacy of a brief motivational intervention for substance-using offenders.

Authors:  Marc T Swogger; Kenneth R Conner; Eric D Caine; Nicole Trabold; Melissa N Parkhurst; Laurel M Prothero; Stephen A Maisto
Journal:  J Consult Clin Psychol       Date:  2016-01-04

Review 3.  Explicating the role of empathic processes in substance use disorders: A conceptual framework and research agenda.

Authors:  Suena H Massey; Rebecca L Newmark; Lauren S Wakschlag
Journal:  Drug Alcohol Rev       Date:  2017-05-10

4.  Delineating the Interplay of Personality Disorders and Health.

Authors:  Ramani S Durvasula; Perry N Halkitis
Journal:  Behav Med       Date:  2017 Jul-Sep       Impact factor: 3.104

5.  Mental Health Services and Public Safety: Substance Abuse Outpatient Visits Were Associated with Reduced Crime Rates in a Swedish Cohort.

Authors:  Natalie Durbeej; Tom Palmstierna; Ingvar Rosendahl; Anne H Berman; Marianne Kristiansson; Clara Hellner Gumpert
Journal:  PLoS One       Date:  2015-09-10       Impact factor: 3.240

6.  Risk Factors for Problematic Behaviors among Forensic Outpatients under the Medical Treatment and Supervision Act in Japan.

Authors:  Kumiko Ando; Takahiro Soshi; Kanako Nakazawa; Takamasa Noda; Takayuki Okada
Journal:  Front Psychiatry       Date:  2016-08-24       Impact factor: 4.157

7.  Psychometric Properties of the Arabic Version of the Drug Use Disorders Identification Test (DUDIT) in Clinical, Prison Inmate, and Student Samples.

Authors:  Anis Sfendla; Btissame Zouini; Dina Lemrani; Anne H Berman; Meftaha Senhaji; Nóra Kerekes
Journal:  Int J Behav Med       Date:  2017-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.